Involved field(IF) vs. extended field (EF) radiotherapy (RT) for patients in early unfavorable stages of Hodgkin's lymphoma (HL): 10-year update of the HD8 trial of the German Hodgkin Study Group (GHSG)

被引：0
|
作者：
Kriz, J. [1 ]
Sasse, S. [2 ]
Klimm, B. [2 ]
Goergen, H. [2 ]
Mueller, R. -P [3 ]
Diehl, V [2 ]
Borchmann, P. [2 ]
Engert, A. [2 ]
Eich, H. -T [1 ]
机构：
[1] Univ Munster, Klin Strahlentherapie, Munster, Germany
[2] Uniklin Koln, Innere Med Klin 1, Cologne, Germany
[3] Uniklin Koln, Klin Strahlentherapie, Cologne, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2012年 / 188卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [21] LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD8 AND HD11 TRIAL
    Sasse, S.
    Broeckelmann, P. J.
    Goergen, H.
    Pluetschow, A.
    Mueller, H.
    Kreissl, S.
    Buerkle, C.
    Borchmann, S.
    Fuchs, M.
    Borchmann, P.
    Engert, A.
    HAEMATOLOGICA, 2016, 101 : 13 - 14
  • [22] Elderly patients with early-unfavorable stage Hodgkin's disease (HD) have a poorer outcome when treated with combined modality treatment and extended field radiotherapy (EF): A retrospective analysis of the German Hodgkin study group.
    Engert, A
    Haverkamp, H
    Eich, HT
    Josting, A
    Pfistner, B
    Diehl, V
    BLOOD, 2004, 104 (11) : 368A - 368A
  • [23] Is an additive Radiotherapy for Patients in advanced Stages of a necessary Hodgkin's Lymphoma? - Final analysis of the HD12 trial of the German Hodgkin Study Group
    Kriz, J.
    Borchmann, P.
    Haverkamp, H.
    Diehl, V
    Mueller, R. -P
    Engert, A.
    Eich, H. -T
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 30 - 30
  • [24] Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IF-RT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial
    Borchmann, Peter
    Engert, Andreas
    Pluetschow, Annette
    Fuchs, Michael
    Markova, Jana
    Lohri, Andreas
    Kral, Zdenek
    Greil, Richard
    Topp, Max
    Villalobos, Matthias
    Zijlstra, Jose
    Soekler, Martin
    Stein, Harald
    Eich, Hans Theodor
    Mueller, Rolf Peter
    Diehl, Volker
    BLOOD, 2008, 112 (11) : 143 - 143
  • [25] Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma:: an analysis from the German Hodgkin Study Group
    Klimm, B.
    Eich, H. T.
    Haverkamp, H.
    Lohri, A.
    Koch, P.
    Boissevain, F.
    Trenn, G.
    Worst, P.
    Duehmke, E.
    Mueller, R. P.
    Mueller-Hermelink, K.
    Pfistner, B.
    Diehl, V.
    Engert, A.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 357 - 363
  • [26] Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10.
    Engert, Andreas
    Diehl, Volker
    Pluetschow, Annette
    Eich, Hans T.
    Herrmann, Richard
    Doerken, Bernd
    Kanz, Lothar
    Greil, Richard
    Markova, Jana
    Fuchs, Michael
    Borchmann, Peter
    Mueller-Hermelink, Hans Konrad
    Mueller, Rolf Peter
    BLOOD, 2009, 114 (22) : 299 - 299
  • [27] Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) HD10 study
    Engert, A.
    Diehl, V
    Pluetschow, A.
    Eich, H.
    Herrmann, R.
    Doerken, B.
    Kanz, L.
    Greil, R.
    Markova, J.
    Fuchs, M.
    Borchmann, P.
    Mueller-Hermeling, H. K.
    Mueller, R. P.
    ONKOLOGIE, 2010, 33 : 124 - 124
  • [28] TWO CYCLES OF ABVD FOLLOWED BY INVOLVED FIELD RADIOTHERAPY WITH 20 GRAY (GY) IS THE NEW STANDARD OF CARE IN THE TREATMENT OF PATIENTS WITH EARLY-STAGE HODGKIN LYMPHOMA: FINAL ANALYSIS OF THE RANDOMIZED GERMAN HODGKIN STUDY GROUP (GHSG) HD10 STUDY
    Engert, A.
    Pluetschow, A.
    Eich, H.
    Herrmann, R.
    Doerken, B.
    Kanz, L.
    Greil, R.
    Markova, J.
    Fuchs, M.
    Borchmann, P.
    Mueller-Hermelink, H.
    Mueller, R.
    Diehl, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 473 - 473
  • [29] DOSE-ESCALATION WITH BEACOPP ESCALATED IS SUPERIOR TO ABVD IN THE COMBINED-MODALITY TREATMENT OF EARLY UNFAVORABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD14 TRIAL
    Borchmann, P.
    Diehl, V.
    Pluetschow, A.
    Von Tresckow, B.
    Markova, J.
    Hitz, F.
    Kra, Z.
    Greil, R.
    Topp, M. S.
    Villalobos, M.
    Zijlstra, J. M.
    Soekler, M.
    Fuchs, M.
    Engert, A.
    ANNALS OF ONCOLOGY, 2011, 22 : 180 - 180
  • [30] Quality control of the involved field (IF)-radiotherapy for patients with early-stage Hodgkin lymphoma based on a central prospective review comparison of the results between two study generations of the German Hodgkin Study Group (GHSG)
    Eich, H. T.
    Kriz, J.
    Bangard, C.
    Bongartz, R.
    Engert, A.
    Mueller, R. -P.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 76 - 76
12345